This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hayden, M. K.
Right arrow Articles by Weinstein, R. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hayden, M. K.
Right arrow Articles by Weinstein, R. A.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, October 2005, p. 5285-5287, Vol. 43, No. 10
0095-1137/05/$08.00+0     doi:10.1128/JCM.43.10.5285-5287.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

Development of Daptomycin Resistance In Vivo in Methicillin-Resistant Staphylococcus aureus

M. K. Hayden,1* K. Rezai,1,2 R. A. Hayes,1 K. Lolans,2 J. P. Quinn,1,2 and R. A. Weinstein1,2

Rush University Medical Center, Chicago, Illinois,1 Stroger (Cook County) Hospital, Chicago, Illinois2

Received 17 May 2005/ Returned for modification 14 June 2005/ Accepted 11 July 2005


arrow
ABSTRACT
 
Daptomycin is a new lipopeptide antibiotic that is rapidly bactericidal against Staphylococcus aureus. We report daptomycin resistance and treatment failure in 2 patients with osteomyelitis due to methicillin-resistant S. aureus. Disk diffusion susceptibility testing failed to detect resistance. Daptomycin at high concentration retained bactericidal activity against resistant isolates.


arrow
TEXT
 
Daptomycin is a cyclic lipopeptide antibiotic that is rapidly bactericidal in vitro against a broad spectrum of gram-positive bacteria. Its unique mechanism of action involves calcium-dependent binding to the bacterial plasma membrane and disruption of membrane function (10). Resistance is rare and the mechanism is not known. Daptomycin was approved by the United States Food and Drug Administration (FDA) in 2003 at the dose of 4 mg/kg of body weight/day for treatment of complicated skin and soft tissue infections caused by susceptible bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) (2). We report daptomycin nonsusceptibility, hereafter referred to as resistance, and treatment failure in two patients with MRSA osteomyelitis. This investigation was reviewed and approved by the Rush University Medical Center and Stroger (Cook County) Hospital institutional review boards.

Patient 1 was an 86-year-old woman with bacteremic MRSA prosthetic knee septic arthritis. She underwent debridement, synovectomy, and revision arthroplasty. Vancomycin was started, but 7 days later bacteremia recurred. Evaluation for a source, including transthoracic echocardiogram, was unrevealing. Vancomycin was discontinued, and daptomycin was started at 6 mg/kg/day, the dose used in a recent clinical trial of bacteremia and infective endocarditis (3). On day 22 of daptomycin therapy, the patient's creatinine clearance declined to 23 ml/min. The daptomycin dosing interval was increased to 48 h (2). Thirteen days later, her infection relapsed with MRSA bacteremia, epidural abscess, vertebral osteomyelitis, and diskitis at the level of the fifth lumbar and first sacral vertebrae. Blood and epidural tissue grew MRSA.

Patient 2 was a 61-year-old woman with MRSA bacteremia and sternal osteomyelitis complicating heart surgery. The infection resolved after 6 weeks of vancomycin therapy but relapsed 4 weeks later with high-grade MRSA bacteremia and osteomyelitis of the fourth and fifth lumbar vertebrae. Her symptoms resolved again after 6 weeks of daptomycin treatment (6 mg/kg/day), but 1 week later MRSA bacteremia recurred.

Twelve MRSA isolates from patient 1 and 15 MRSA isolates from patient 2 were available. Daptomycin disks (30 µg) and powder were obtained from Cubist Pharmaceuticals, Lexington, MA. Susceptibility testing, including time-kill experiments, was done using National Committee for Clinical Laboratory Standards guidelines (7, 8, 9). All testing was repeated at least three times.

Disk diffusion assays using Mueller-Hinton agar from two different manufacturers (Remel, Lenexa, KS, and BD Diagnostics, Cockeysville, MD) and the FDA-approved breakpoint of 16 mm (2, 9) indicated that all isolates were susceptible to daptomycin (Table 1). At the time of each patient's clinical and microbiologic failure, available isolates were reevaluated by a microdilution method using Mueller-Hinton broth supplemented with 50 mg/liter Ca2+ and 10 mg/liter Mg2+. One of patient 2's pretreatment isolates was resistant to daptomycin, as were all posttreatment isolates from both patients (Table 1). Resistance was stable after 30 serial subcultures on antibiotic-free tryptic soy agar containing 5% sheep blood (Remel). One of patient 2's posttreatment isolates displayed heterogeneous intermediate vancomycin resistance; the vancomycin MIC, determined by a microdilution method (8), was 4 µg/ml, but the isolate grew on brain heart infusion agar containing 6 µg/ml vancomycin (Remel), and also grew at vancomycin concentrations as high as 16 µg/ml in population analysis profile assays (14).


View this table:
[in this window]
[in a new window]
  		TABLE 1. Daptomycin susceptibility testing of clinical methicillin-resistant Staphylococcus aureus isolates

Pulsed-field gel electrophoresis (6) revealed identical patterns for all of patient 2's isolates. Likewise, all of patient 2's isolates were identical. However, the pulsed-field gel electrophoresis pattern of patient 1's isolates differed from patient 2's by more than six bands, indicating that the two patients were infected by unrelated MRSA strains (12).

We tested representative isolates in time-kill experiments (7). Daptomycin consistently showed bactericidal activity against susceptible and resistant isolates when tested at concentrations four times higher than the MIC, although regrowth at 24 h was common (Fig. 1). We determined the daptomycin MIC for 42 representative colonies picked from regrowth plates; the MIC of one of patient 2's susceptible isolates was found to have increased from 0.5 µg/ml to 4 µg/ml.



View larger version (18K):
[in this window]
[in a new window]
  		FIG. 1. Time-kill experiments with representative daptomycin-susceptible and daptomycin-resistant methicillin-resistant Staphylococcus aureus isolates. (A) Daptomycin-susceptible isolate from patient 1. (B) Daptomycin-resistant isolate from patient 1. (C) Daptomycin-susceptible isolate from patient 2. (D) Daptomycin-resistant isolate from patient 2. Abbreviations: C, Growth control without daptomycin; 1x MIC, 2x MIC, and 4x MIC, daptomycin concentrations tested were equal to, twice, and four times higher than the MIC of daptomycin for the isolate, respectively.

Modified population analysis profile testing (10) of susceptible isolates demonstrated heterogeneous growth below the isolate MIC but did not identify a daptomycin-resistant subpopulation. Doubling times for susceptible and resistant isolates were comparable (13).

To our knowledge, this is the first report of de novo daptomycin resistance associated with treatment failure of S. aureus and only the second report of clinical failure associated with the development of daptomycin resistance during therapy (5). The bone infections in our patients may have disposed them to treatment failure. Clinical experience with daptomycin treatment of human osteomyelitis is anecdotal (11) and outcomes are mixed. In an experimental rabbit model, Mader and Adams demonstrated similar microbiologic eradications of MRSA from infected tibias of animals treated with vancomycin or daptomycin at comparable peak plasma levels but a poorer radiologic response to daptomycin. In that study, daptomycin concentrations in infected bone were lower than vancomycin concentrations and no daptomycin could be measured in healthy bone (4). Failure to debride patient 2's infection may also have contributed to relapse.

Disk diffusion susceptibility testing did not detect daptomycin resistance in these two MRSA strains. This may be due to varied calcium concentrations in commercial Mueller-Hinton agar. Because of the unreliability of the disk diffusion method, it is no longer recommended, and the distribution of disks for investigational use has ceased.

We do not know the mechanism of daptomycin resistance in these isolates, nor do we know if the mechanisms of daptomycin resistance and the heterogeneous intermediate vancomycin resistance seen in patient 2's MRSA strain are related. Another study found that daptomycin retained good activity against S. aureus with reduced vancomycin susceptibility (1).

Based on our experience, we urge caution in the use of daptomycin for treatment of osteomyelitis; e.g., use the maximum tolerated dose and monitor the patient closely for evidence of relapse. We also recommend testing the daptomycin susceptibilities of clinical isolates of S. aureus by an FDA-cleared MIC device before initiating therapy and in cases of microbiologic failure.


arrow
ACKNOWLEDGMENTS
 
This study was funded in part by a grant from Cubist Pharmaceuticals, Inc., which had no role in the study design; in the collection, analysis or interpretation of data; in the writing of the report; or in the decision to submit the paper for publication.


arrow
FOOTNOTES
 
* Corresponding author. Mailing address: Rush University Medical Center, 1653 W. Congress Parkway, Chicago, IL 60612. Phone: (312) 942-5445. Fax: (312) 942-6787. E-mail: mhayden{at}rush.edu. Back


arrow
REFERENCES
 
    1
  1. Akins, R. L., and M. J. Rybak. 2001. Bactericidal activities of two daptomycin regimens against clinical strains of glycopeptide intermediate-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and methicillin-resistant Staphylococcus aureus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob. Agents Chemother. 45:454-459.[Abstract/Free Full Text]
    2. 2
  2. Cubist Pharmaceuticals, Inc. 2003. Daptomycin (Cubicin) package literature. Cubist Pharmaceuticals, Inc., Lexington, Mass.
    3. 3
  3. Cubist Pharmaceuticals, Inc.. Daptomycin in the treatment of subjects with infective endocarditis or bacteremia due to S. aureus. ClinicalTrials.gov, identifier NCT00093067. [Online.] http://clinicaltrials.gov/show/NCT00093067.
    4. 4
  4. Mader, J. T., and K. Adams. 1989. Comparative evaluation of daptomycin (LY146032) and vancomycin in the treatment of experimental methicillin-resistant Staphylococcus aureus osteomyelitis in rabbits. Antimicrob. Agents Chemother. 33:689-692.[Abstract/Free Full Text]
    5. 5
  5. Mangili, A., I. Bica, D. R. Snydman, and D. H. Hamer. 2005. Daptomycin-resistant, methicillin-resistant Staphylococcus aureus bacteremia. Clin. Infect. Dis. 40:1058-1060.[CrossRef][Medline]
    6. 6
  6. Matushek, M. G., M. J. Bonten, and M. K. Hayden. 1996. Rapid preparation of bacterial DNA for pulsed-field gel electrophoresis. J. Clin. Microbiol. 34:2598-2600.[Abstract]
    7. 7
  7. National Committee for Clinical Laboratory Standards. 1999. Methods for determining bactericidal activity. Approved standard M26-A. Clinical and Laboratory Standards Institute, Wayne, Pa.
    8. 8
  8. National Committee for Clinical Laboratory Standards. 2003. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard, 6th ed., M7-A6. Clinical and Laboratory Standards Institute, Wayne, Pa.
    9. 9
  9. National Committee for Clinical Laboratory Standards. 2003. Performance standards for antimicrobial disk susceptibility tests. Approved standard, 8th ed., M2-A8. Clinical and Laboratory Standards Institute, Wayne, Pa.
    10. 10
  10. Silverman, J. A., N. Oliver, O. Andrew, and T. Li. 2001. Resistance studies with daptomycin. Antimicrob. Agents Chemother. 45:1799-1802.[Abstract/Free Full Text]
    11. 11
  11. Stienecker, S., and G. Sriramenini. 2004. Use of daptomycin for osteomyelitis in Lima, Ohio. OPAT Newsl. 4(2). [Online.] http://www.opat.com/Articles/September/Stienecker.htm. Accessed 28 March 2005.
    12. 12
  12. Tenover, F. C., R. D. Arbeit, R. V. Goering, P. A. Mickelsen, B. E. Murray, D. E. Persing, and B. Swaminathan. 1995. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J. Clin. Microbiol. 33:2233-2239.[Medline]
    13. 13
  13. Todar, K. 2002. Growth of bacterial populations. In Todar's online textbook of bacteriology. [Online.] http://textbookofbacteriology.net/growth.html. Accessed 10 September 2004.
    14. 14
  14. Walsh, T. R., A. Bolmstrom, A. Qwarnstrom, P. Ho, M. Wootton, R. A. Howe, A. P. MacGowan, and D. Diekema. 2001. Evaluation of current methods for detection of staphylococci with reduced susceptibility to glycopeptides. J. Clin. Microbiol. 39:2439-2444.[Abstract/Free Full Text]

Journal of Clinical Microbiology, October 2005, p. 5285-5287, Vol. 43, No. 10
0095-1137/05/$08.00+0     doi:10.1128/JCM.43.10.5285-5287.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Vidaillac, C., Leonard, S. N., Rybak, M. J. (2009). In Vitro Activity of Ceftaroline against Methicillin-Resistant Staphylococcus aureus and Heterogeneous Vancomycin-Intermediate S. aureus in a Hollow Fiber Model. Antimicrob. Agents Chemother. 53: 4712-4717 [Abstract] [Full Text]  
  • Miro, J. M., Garcia-de-la-Maria, C., Armero, Y., Soy, D., Moreno, A., del Rio, A., Almela, M., Sarasa, M., Mestres, C. A., Gatell, J. M., Jimenez de Anta, M. T., Marco, F., and the Hospital Clinic Experimental Endocarditis, (2009). Addition of Gentamicin or Rifampin Does Not Enhance the Effectiveness of Daptomycin in Treatment of Experimental Endocarditis Due to Methicillin-Resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 53: 4172-4177 [Abstract] [Full Text]  
  • Yang, S.-J., Xiong, Y. Q., Dunman, P. M., Schrenzel, J., Francois, P., Peschel, A., Bayer, A. S. (2009). Regulation of mprF in Daptomycin-Nonsusceptible Staphylococcus aureus Strains. Antimicrob. Agents Chemother. 53: 2636-2637 [Abstract] [Full Text]  
  • Kirby, A., Mohandas, K., Broughton, C., Neal, T. J., Smith, G. W., Pai, P., Nistal de Paz, C. (2009). In vivo development of heterogeneous glycopeptide-intermediate Staphylococcus aureus (hGISA), GISA and daptomycin resistance in a patient with meticillin-resistant S. aureus endocarditis. J Med Microbiol 58: 376-380 [Abstract] [Full Text]  
  • Camargo, I. L. B. d. C., Neoh, H.-M., Cui, L., Hiramatsu, K. (2008). Serial Daptomycin Selection Generates Daptomycin-Nonsusceptible Staphylococcus aureus Strains with a Heterogeneous Vancomycin-Intermediate Phenotype. Antimicrob. Agents Chemother. 52: 4289-4299 [Abstract] [Full Text]  
  • Hawkey, P. M. (2008). Pre-clinical experience with daptomycin. J Antimicrob Chemother 62: iii7-iii14 [Abstract] [Full Text]  
  • Levine, D. P. (2008). Clinical experience with daptomycin: bacteraemia and endocarditis. J Antimicrob Chemother 62: iii35-iii39 [Abstract] [Full Text]  
  • Warren, R. E. (2008). Daptomycin in endocarditis and bacteraemia: a British perspective. J Antimicrob Chemother 62: iii25-iii33 [Abstract] [Full Text]  
  • Wargo, K. A., Eiland, E. H. III, Eiland, L. S. (2008). Management and Treatment Considerations for Infections Caused by Methicillin-Resistant Staphylococcus aureus. Journal of Pharmacy Practice 21: 324-336 [Abstract]  
  • Bailey, J., Summers, K. M. (2008). Dalbavancin: A new lipoglycopeptide antibiotic. Am J Health Syst Pharm 65: 599-610 [Abstract] [Full Text]  
  • Rose, W. E., Leonard, S. N., Sakoulas, G., Kaatz, G. W., Zervos, M. J., Sheth, A., Carpenter, C. F., Rybak, M. J. (2008). Daptomycin Activity against Staphylococcus aureus following Vancomycin Exposure in an In Vitro Pharmacodynamic Model with Simulated Endocardial Vegetations. Antimicrob. Agents Chemother. 52: 831-836 [Abstract] [Full Text]  
  • Montero, C. I., Stock, F., Murray, P. R. (2008). Mechanisms of Resistance to Daptomycin in Enterococcus faecium. Antimicrob. Agents Chemother. 52: 1167-1170 [Abstract] [Full Text]  
  • Huang, Y.-T., Hsiao, C.-H., Liao, C.-H., Lee, C.-W., Hsueh, P.-R. (2008). Bacteremia and Infective Endocarditis Caused by a Non-Daptomycin-Susceptible, Vancomycin-Intermediate, and Methicillin-Resistant Staphylococcus aureus Strain in Taiwan. J. Clin. Microbiol. 46: 1132-1136 [Abstract] [Full Text]  
  • Jones, T., Yeaman, M. R., Sakoulas, G., Yang, S.-J., Proctor, R. A., Sahl, H.-G., Schrenzel, J., Xiong, Y. Q., Bayer, A. S. (2008). Failures in Clinical Treatment of Staphylococcus aureus Infection with Daptomycin Are Associated with Alterations in Surface Charge, Membrane Phospholipid Asymmetry, and Drug Binding. Antimicrob. Agents Chemother. 52: 269-278 [Abstract] [Full Text]  
  • Julian, K., Kosowska-Shick, K., Whitener, C., Roos, M., Labischinski, H., Rubio, A., Parent, L., Ednie, L., Koeth, L., Bogdanovich, T., Appelbaum, P. C. (2007). Characterization of a Daptomycin-Nonsusceptible Vancomycin-Intermediate Staphylococcus aureus Strain in a Patient with Endocarditis. Antimicrob. Agents Chemother. 51: 3445-3448 [Abstract] [Full Text]  
  • Rose, W. E., Rybak, M. J., Kaatz, G. W. (2007). Evaluation of daptomycin treatment of Staphylococcus aureus bacterial endocarditis: an in vitro and in vivo simulation using historical and current dosing strategies. J Antimicrob Chemother 60: 334-340 [Abstract] [Full Text]  
  • Goldstein, F. (2007). The potential clinical impact of low-level antibiotic resistance in Staphylococcus aureus. J Antimicrob Chemother 59: 1-4 [Abstract] [Full Text]  
  • Aiello, A. E., King, N. B., Foxman, B. (2006). Ethical Conflicts in Public Health Research and Practice: Antimicrobial Resistance and the Ethics of Drug Development. AJPH 96: 1910-1914 [Abstract] [Full Text]  
  • Jevitt, L. A., Thorne, G. M., Traczewski, M. M., Jones, R. N., McGowan, J. E. Jr., Tenover, F. C., Brown, S. D. (2006). Multicenter Evaluation of the Etest and Disk Diffusion Methods for Differentiating Daptomycin-Susceptible from Non-Daptomycin-Susceptible Staphylococcus aureus Isolates.. J. Clin. Microbiol. 44: 3098-3104 [Abstract] [Full Text]  
  • Fowler, V. G. Jr., Boucher, H. W., Corey, G. R., Abrutyn, E., Karchmer, A. W., Rupp, M. E., Levine, D. P., Chambers, H. F., Tally, F. P., Vigliani, G. A., Cabell, C. H., Link, A. S., DeMeyer, I., Filler, S. G., Zervos, M., Cook, P., Parsonnet, J., Bernstein, J. M., Price, C. S., Forrest, G. N., Fatkenheuer, G., Gareca, M., Rehm, S. J., Brodt, H. R., Tice, A., Cosgrove, S. E., the S. aureus Endocarditis and Bacteremia Study Gr, (2006). Daptomycin versus Standard Therapy for Bacteremia and Endocarditis Caused by Staphylococcus aureus.. NEJM 355: 653-665 [Abstract] [Full Text]  
  • Denis, O., Deplano, A., Nonhoff, C., Hallin, M., De Ryck, R., Vanhoof, R., De Mendonca, R., Struelens, M. J. (2006). In Vitro Activities of Ceftobiprole, Tigecycline, Daptomycin, and 19 Other Antimicrobials against Methicillin-Resistant Staphylococcus aureus Strains from a National Survey of Belgian Hospitals.. Antimicrob. Agents Chemother. 50: 2680-2685 [Abstract] [Full Text]  
  • Tyrrell, K. L., Citron, D. M., Warren, Y. A., Fernandez, H. T., Merriam, C. V., Goldstein, E. J. C. (2006). In Vitro Activities of Daptomycin, Vancomycin, and Penicillin against Clostridium difficile, C. perfringens, Finegoldia magna, and Propionibacterium acnes.. Antimicrob. Agents Chemother. 50: 2728-2731 [Abstract] [Full Text]  
  • Friedman, L., Alder, J. D., Silverman, J. A. (2006). Genetic Changes That Correlate with Reduced Susceptibility to Daptomycin in Staphylococcus aureus.. Antimicrob. Agents Chemother. 50: 2137-2145 [Abstract] [Full Text]  
  • Jorgensen, J. H., Crawford, S. A. (2006). Assessment of Two Commercial Susceptibility Test Methods for Determination of Daptomycin MICs.. J. Clin. Microbiol. 44: 2126-2129 [Abstract] [Full Text]  

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hayden, M. K.
Right arrow Articles by Weinstein, R. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hayden, M. K.
Right arrow Articles by Weinstein, R. A.

Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»